Dear Valued Customers,

This is the ODM Sales Team at Raphas.

 As we approach the end of 2024, I understand this is a busy time for many.

However, as we prepare for the upcoming year, I would like to take this opportunity

to explore a valuable collaboration with your esteemed company.

Raphas specializes in the production of cutting edge microneedle patch products,

uniquely manufactured using our advanced proprietary technology.

Our differentiated products are sold under our own brand as well as through ODM partnerships

in markets such as Korea, the United States, Japan, and Europe.

We would like to propose a collaboration with your fascinating brands.

We hope you will consider this proposal positively,

and we look forward to discussing this potential synergy further.

1. Proven product reliability through years of partnerships

Raphas is proud to highlight Acropass, our proprietary brand,

which has won the Olive Young Awards for five consecutive years,

which is hosted by the most popular beauty retail chain in Korea.

With over five years of partnerships with clients in both domestic and U.S. markets,

our products are recognized for their exceptional quality and efficacy.

Our commitment to innovation and quality has driven us to achieve a record

of 157 million products sold over 11 years without a single skin irritation claim.

This unparalleled track record reflects the trust of companies seeking to deliver

superior value and long-term growth.

As a global leader in microneedle technology,

Raphas continues to set the standard for innovation, quality, and high-volume production,

cementing our position as a trusted partner in the microneedle industry.

2. What sets Raphas apart from other manufacturers?

In 2023, Raphas became the first microneedle patch manufacturer to pass the U.S. FDA OTC audit.

This milestone enabled the production and sale of OTC drugs via Acropass and U.S. partnerships,

backed by strict pharmaceutical-grade quality systems.

With over 60 patents, our hyaluronic acid microneedle technology leads the global market.

In 2024, Raphas’ innovation was recognized with the “World Class Product of Korea” designation by KOTRA,

further validating our exceptional quality and technology.

3. An overview of the basic concepts of Dissolving Microneedle

Dissolving microneedle is a new transdermal drug delivery technology that forms fine needle structures

using hyaluronic acid to effectively deliver active ingredients to the target area.

Raphas' patented DEN (Droplet Extension) method differs from traditional molding techniques

by using the viscosity of ingredients and air to naturally create needles.

This allows for the stable inclusion of sensitive ingredients such as Vitamin C, retinol, and peptides.

Additionally, DEN is more efficient than other methods, producing needles that are longer and finer,

which enhances product absorption.

With this proven technology and successful track record,

we are confident that we can be a great partner that will elevate your brand.

We kindly ask you to consider this proposal despite your busy schedule.

Thank you very much for taking the time and showing interest in our company.

Best regards

Raphas ODM Sales Team